BR 3006
Alternative Names: BR-3006; BR-3006-1; BR-3006-2; BR-3006-3Latest Information Update: 28 Aug 2023
At a glance
- Originator Boryung Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetes mellitus
Most Recent Events
- 22 Jul 2023 Phase-I clinical trials in Diabetes mellitus (In volunteers) in South Korea (PO) (NCT05951946)
- 19 Jul 2023 Preclinical trials in Diabetes mellitus in South Korea (PO), prior to July 2023 ((Boryung Pharmaceutical pipeline, July 2023)
- 19 Jul 2023 Boryung Pharmaceutical plans a phase I trial for Diabetes mellitus (In volunteers) in South Korea (PO) (NCT05951946)